Quantcast
Last updated on April 24, 2014 at 11:55 EDT

BiologicsMD, Inc. Announces The Appointment of J. David Owens as Chief Executive Officer

July 16, 2013

29-year pharmaceutical and biotechnology veteran joins the BiologicsMD™ team to advance promising bone-building drug towards clinical development and to seek strategic industry partnerships.

Fayetteville, Arkansas (PRWEB) July 16, 2013

BiologicsMD, Inc., a privately held drug discovery company developing innovative biologic therapeutics for improving bone health, announced that it has appointed J. David Owens to the company’s newly created CEO position. Mr. Owens brings a long and successful track record within both the pharmaceutical and biotechnology industries, having managed billion dollar business units within multi-national pharmaceutical companies and also built early stage businesses that successfully attracted capital and strategic partners.

Most recently, Mr. Owens was the Chief Business Officer for Novira Therapeutics, Inc., a privately held antiviral drug discovery company developing innovative, first-in-class therapeutics for the treatment of viral diseases. While there, he co-led a syndicated angel investment in 2011 and then a Series A financing in 2012. Prior to Novira, Mr. Owens held executive positions as Senior Vice President, and Business Unit Head of the Surgical Products Division at King Pharmaceuticals (now part of Pfizer) and prior to that as Vice President of Global Marketing & Medical Affairs at Aventis Pharma (now part of Sanofi). Earlier in his career, Mr. Owens held commercial operations roles at Genentech, Merck and Abbott Labs. He is also a member of the Selection Team and a Business Advisor to the University City Science Center (QED Program), one of the United State’s oldest urban incubators located in Philadelphia, PA. Mr. Owens is a graduate of the University of Wisconsin, School of Pharmacy and a Registered Pharmacist.

“I’m very excited to join the BiologicsMD team at this very important stage in advancing the company’s lead development drug, PTH-CBD™, towards the clinic,” said Mr. Owens. “The team and the Board have done an excellent job of getting the technology to the preclinical stage. Now we will prove that PTH-CBD™ is a novel and important new tool in treating human disease.”

“We are very pleased that David has joined the BiologicsMD team and will guide the company into its next stage of development. David brings an outstanding set of skills and experiences and also has the industry contacts needed to help BiologicsMD obtain strategic partnerships as the company approaches the clinic,” stated Dr. Calvin Goforth, Chairman of the BiologicsMD, Inc. Board of Directors.

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, that selectively binds to bone and stimulates new bone growth. PTH-CBD is a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD binds to type 1 collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10928698.htm


Source: prweb